The toxicities associated with CAR T-cell therapy are unique but manageable, said Schuster, director of lymphoma program and Robert and Margarita Louis-Dreyfus professor in chronic lymphocytic leukemia and lymphoma clinical care and research at University of Pennsylvania.

“All three of these products and this treatment approach offers patients — for whom we don’t have existing therapies that are adequate — the potential in at least a third of cases to have a prolonged disease-free remission after a single course of therapy,” Schuster said.

Disclosure:Shuster reports research support from/consultant roles with Celgene, Gilead, Merck and Novartis.

The toxicities associated with CAR T-cell therapy are unique but manageable, said Schuster, director of lymphoma program and Robert and Margarita Louis-Dreyfus professor in chronic lymphocytic leukemia and lymphoma clinical care and research at University of Pennsylvania.

“All three of these products and this treatment approach offers patients — for whom we don’t have existing therapies that are adequate — the potential in at least a third of cases to have a prolonged disease-free remission after a single course of therapy,” Schuster said.

Disclosure:Shuster reports research support from/consultant roles with Celgene, Gilead, Merck and Novartis.